Orchestra Biomed Holdings Inc (OBIO)

Orchestra Biomed Holdings, Inc. is a healthcare company focused on developing biomedical technologies and medical devices in the United States. Its pipeline includes Atrioventricular Interval Modulation, a bioelectronic therapy candidate intended to lower blood pressure, and Virtue Sirolimus AngioInfusion Balloon, which is being developed for atherosclerotic artery disease. The company is also working on Cardiac Neuromodulation Therapy for heart failure and other potential clinical uses, including urology and osteoarthritis, along with CNT-HF, a product candidate designed to reduce chronic sympathetic nervous system activity in heart failure. In addition, Orchestra BioMed develops minimally invasive surgery enabling devices such as FreeHold and the Pure-Vu system for gastrointestinal cleansing during colonoscopy and upper gastrointestinal endoscopy procedures. The company has collaboration agreements with Medtronic and Terumo related to AVIM therapy and Virtue SAB, and it was founded in 2018. It is headquartered in New Hope, Pennsylvania.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.